Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R6EQ
|
|||
| Former ID |
DIB011385
|
|||
| Drug Name |
Bivatuzumab mertansine
|
|||
| Synonyms |
BIWI-1; Bivatuzumab-DM1
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Terminated | [1] | |
| Company |
Boehringer Ingelheim International GmbH
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular matrix receptor III (CD44) | Target Info | . | [1] |
| KEGG Pathway | ECM-receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Shigellosis | ||||
| Epstein-Barr virus infection | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Pathway Interaction Database | Osteopontin-mediated events | |||
| a4b7 Integrin signaling | ||||
| Reactome | Degradation of the extracellular matrix | |||
| Cell surface interactions at the vascular wall | ||||
| Integrin cell surface interactions | ||||
| Hyaluronan uptake and degradation | ||||
| Interferon gamma signaling | ||||
| WikiPathways | Senescence and Autophagy in Cancer | |||
| Wnt Signaling Pathway and Pluripotency | ||||
| Glycosaminoglycan metabolism | ||||
| Extracellular matrix organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.